Preoperative Treatment of Patients With High Risk Thymoma
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is a phase II study for patients with thymoma or thymic carcinoma thought to be at
significant risk for recurrence following surgical removal. This study involves the use of
combined chemotherapy and radiation therapy prior to surgery, in hopes of increasing the
chances of complete resection. The chemoradiotherapy protocol is one which has been used
extensively for other diseases, and the side effects are therefore well-documented. Patients
with thymomas thought to be at significant risk for recurrence (by x-ray and pathology
criteria) will be allowed to participate, and will undergo combined chemotherapy with
radiation to the chest followed by surgical removal of the tumor and postoperative
chemotherapy. The main outcome measured will be the rate of pathological complete response
(e.g. no active tumor in the resected specimen) to the preoperative treatment. Patients will
receive postoperative treatment based on surgical and pathologic criteria.